Resveratrol is a strong candidate for explaining an irreversible correlation between red wine consumption and coronary heart disease. The present study examined the effect of "-viniferin, a dehydrodimer of resveratrol, on vascular smooth muscle cells (VSMCs), because "-viniferin functions are poorly understood in spite of its comparable content to resveratrol in red wines and grapes. Both "-viniferin and resveratrol inhibited platelet-derived growth factor-induced cell proliferation, migration, and reactive oxygen species (ROS) production, in addition to inducing nitric oxide generation. "-Viniferin was more effective than resveratrol in these effects, except for inhibiting ROS production. The compounds also increased the expression of the antioxidant enzyme, hemeoxygenase-1, via transcription factor Nrf2. The phosphatidylinositol 3-kinase-Akt pathway was implicated in resveratrol-dependent nuclear Nrf2 accumulation, whereas extracellular signal-regulated kinase and p38 were involved in "-viniferin-induced Nrf2 accumulation. These data suggest that "-viniferin may function more effectively than resveratrol in different mechanisms and cooperatively with resveratrol in preventing atherosclerosis.
Resveratrol (3, 4 0 ,5-trihydroxy stilbene) is an antioxidative polyphenol produced in grapes and related plants, and is especially abundant in grape skin and red wine. 1, 2) Accumulating evidence indicates that resveratrol is a beneficial compound to prevent the initiation and progression of lifestyle-related diseases such as atherosclerosis and diabetes. [2] [3] [4] Epidemiological studies have also shown that red wine consumption was irreversibly correlated to a risk of coronary heart disease. 5) In practice, resveratrol inhibits the oxidation of human low-density lipoproteins, 6, 7) platelet aggregation, 8) and the proliferation of vascular smooth muscle cells (VSMCs) [9] [10] [11] [12] [13] [14] which can prevent the pathogenesis of atherosclerosis. Resveratrol is therefore believed to be a strong candidate for explaining the ''French paradox'' that indicates the reduction in coronary heart disease observed with red wine drinkers.
In contrast to resveratrol, the functions of its oligomers, including "-viniferin, a dehydrodimer of resveratrol, have not yet been well investigated, although the "-viniferin content is comparable to or higher than that of resveratrol, depending on the type of red wine and the stage of noble rot development of the grapes; 15, 16) "-viniferin is formed from resveratrol by oxidative processes. As examples, the red wine named Merlot 2000 contains 4.32 mg/L of "-viniferin and 3.04 mg/L of trans-resveratrol, while the red wine called Cabernet Sauvignon 2000 contains 1.23 mg/L of "-viniferin and an undetectable level of resveratrol. 16) The content of "-viniferin during noble rot development in Sauvignon and Semillon grapes respectively reaches six-fold and 18-fold that of trans-resveratrol. 15) Several biological functions of "-viniferin have so far been demonstrated; for example, "-viniferin exhibited hepatoprotective activity in cultured rat hepatocytes, 17) and had a potent inhibitory effect against lipoxygenase and the oxidation of low-density lipoprotein and highdensity lipoprotein. 18, 19) Resveratrol and its oligomers, including "-viniferin, have also been suggested to show anti-proliferative and pro-apoptotic effects on cancer cells such as human and murine leukemia cells, [20] [21] [22] human hepatoma HepG2 cells, 23) and human colon cancer cells. 22, 24, 25) Although "-viniferin was ineffective or less effective than resveratrol towards these cancer cells, [20] [21] [22] [23] [24] [25] it was more effective than resveratrol in inducing the relaxation of isolated rat thoracic aorta preparations.
26) "-Viniferin has also been reported as a more potent antioxitant than resveratrol in vitro.
27) It is therefore likely that the potency of the effects of these two compounds may be dependent on the cell type and/or the target molecule. These data raise the possibility that "-viniferin may be more effective than resveratrol in preventing the pathogenesis of atherosclerosis and that "-viniferin may also be important in addition to resveratrol for explaining the ''French paradox.'' y To whom correspondence should be addressed. Fax: +81-29-853-7723; E-mail: hitomy1@sakura.cc.tsukuba.ac.jp Abbreviations: DAF-2DA, diaminofluorescein-2 diacetate; DCF-DA, 2 0 ,7 0 -dichlorofluorescein diacetate; DMEM, Dulbecco's modified Eagle's medium; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; HBSS, Hanks' balanced salt solution; HO-1, hemeoxygenase-1; iNOS, inducible nitric oxide synthase; L-NAME, NG-nitro-L-arginine methyl ester; MAPK, mitogen-activated protein kinase; NO, nitric oxide; Nrf2, nuclear factor-E2-related factor 2; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species; VSMCs, vascular smooth muscle cells; ZnPP IX, zinc protoporphyrin IX The present study examines the direct effect of "-viniferin and resveratrol on the proliferation and migration of VSMCs induced by platelet-derived growth factor (PDGF) and the molecular mechanisms involved, because these phenomena are closely associated with the pathogenesis of atherosclerosis. We particularly focus on a comparison of the potency between the two compounds of these effects.
Materials and Methods
Materials. "-Viniferin was kindly provided by Sun Bright Co. (Tokyo, Japan), and trans-resveratrol was purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin and streptomycin, Hanks' balanced salt solution (HBSS), 2 0 ,7 0 -dichlorofluorescein diacetate (DCF-DA) and L-arginine were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Diaminofluorescein-2 diacetate (DAF-2DA) was obtained from Daiichi Pure Chemicals Co. (Tokyo, Japan). The antibodies were obtained from the following suppliers: anti-phospho-AKT, anti-phospho-ERK1/2, and anti-phospho-p38 from Cell Signaling Technology (Beverly, MA, USA); anti-inducible nitric oxide synthase (iNOS) from BD Biosciences Pharmingen (San Diego, CA, USA); anti-nuclear factor-E2-related factor 2 (Nrf2) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and anti-hemeoxigenase-1 (HO-1) from Calbiochem. NG-nitro-L-arginine methyl ester (L-NAME) was obtained from Wako Pure Chemical Industries (Osaka, Japan), and zinc protoporphyrin IX (ZnPPIX), LY294002, U0126, and SB202190 were from Calbiochem.
Cell culture. VSMCs were obtained from the thoracic aorta of adult Sprague-Dawley rats as previously described, 28) and cultured in DMEM supplemented with 10% FBS, 100 units/mL penicillin and 100 mg/mL streptomycin at 37 C in a humidified 5% CO 2 atmosphere. The responses of VSMCs to the compounds were analyzed between passages 8 and 10 after a 48-h incubation in DMEM containing 0.1% FBS.
Cell proliferation assay. Cell proliferation was performed by using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) reduction assay kit (Cell Titer 96 aqueous nonradioactive cell proliferation assay, Promega). The stimulators resveratrol and "-viniferin, and the inhibitor ZnPP IX were dissolved in dimethyl sulfoxide (DMSO), and then added to the medium at a final DMSO concentration of 1%. The same final concentration of DMSO was used in place of these reagents for control treatments. PDGF and L-NAME were dissolved in water. The cell proliferation assay was not affected by DMSO under these experimental conditions. Cell migration assay. Cell migration was determined by using a modified Boyden chamber method with the Transwell system (Corning Coastar, Cambridge, MA, USA). The lower side of a polyvinylpyrrolidone-free polycarbonate membrane with a pore size of 8.0 mm was coated with fibronectin. Serum-starved cells (1:5 Â 10 5 cells/well), which had been preincubated with or without various reagents for 30 min, were added to the upper chamber. The upper chamber with cells was inserted into the bottom chamber filled with the medium and incubated in the presence or absence of PDGF (20 ng/mL) for 5 h. Cells that had migrated to the bottom surface of the membrane were fixed in methanol, stained with hematoxylin and eosin, and counted in five representative fields under a microscope. As already described, the stimulators resveratrol and "-viniferin were dissolved in DMSO and then added to the medium at a final DMSO concentration of 0.1%. The same final concentration of DMSO was used in place of these reagents. The cell migration assay was not affected by DMSO under these experimental conditions.
Measurement of intracellular ROS. The generation of intracellular reactive oxygen species (ROS) was detected by using the oxidantsensitive probe DCF-DA that was distributed throughout the cytosol and emitted green fluorescence when oxidized with ROS. 29) Serumstarved VSMCs (2 Â 10 5 cells/dish) in 3.5-cm dishes were incubated with or without a compound for 24 h, rinsed twice with HBSS, treated with 5 mM DCF-DA for 15 min, and left unstimulated or stimulated with PDGF (20 ng/mL) for 15 min. The fluorescence was then monitored by confocal laser scanning microscopy, using an excitation wavelength of 488 nm and an emission wavelength of 500-630 nm. Data are expressed as the change relative to the initial fluorescence. Images were collected and analysed by the TCPSP2 confocal scanning system (Leica). As already described, the stimulators resveratrol and "-viniferin were dissolved in DMSO and then added to the medium at a final DMSO concentration of 0.1%. The same final concentration of DMSO was used in place of these reagents. The measurement of intracellular ROS was not affected by DMSO under these experimental conditions.
Measurement of nitric oxide (NO) production. The DAF-2DA fluorescence reagent was used to measure NO production. 30) Briefly, VSMCs (3 Â 10 3 cells/well) plated on to a 96-well plate were loaded with 10 mM DAF-2DA for 30 min and then incubated for 5 h with 100 mM L-arginine in the presence of different concentrations of resveratrol or "-viniferin. The production of NO was evaluated by recording the fluorescence at 485 nm as excitation and 530 nm as emission with a luminescence spectrophotometer (PerkinElmer, Waltham, MA, USA). The stimulators resveratrol and "-viniferin were dissolved in DMSO and then added to the medium at a final DMSO concentration of 0.5%. The same final concentration of DMSO was used in place of these reagents. The measurement of nitric oxide production was not affected by DMSO under these experimental conditions.
Preparation of nuclear extracts. After being treated with resveratrol or "-viniferin, cells were washed with ice-cold PBS, scraped, transferred to microtubes, and allowed to swell by adding 100 mL of a hypotonic buffer consisting of 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.4% Nonidet P-40, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonylfluoride (PMSF). The lysates obtained were incubated on ice for 10 min and centrifuged at 14,000 rpm and 4 C for 3 min. Pellets containing the crude nuclei were resuspended in 50 mL of an extraction buffer consisting of 20 mM HEPES (pH 7.9), 0.4 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol and 0.5 mM PMSF, and then incubated on ice for 20 min. Each resulting sample was centrifuged at 14,000 rpm for 10 min to obtain a supernatant containing the nuclear fractions and was stored at À80 C until required.
Knockdown of Nrf2. Serum-starved VSMCs (1 Â 10 5 cells/well) plated on 35-mm dishes were transected with 100 mM of Nrf2-specific siRNA (Eurogentec, Belgium) or a scrambled control (Invitrogen, Carlsbad, CA, USA), using LipofectamineÔ RNAiMAX (Invitrogen), and then left for 48 h to allow turnover of the residual Nrf2 protein and to block de novo synthesis of Nrf2. The cells were then used for the experiments, successful knockdown of the target proteins being confirmed by western blotting.
Western blotting. After incubating with the reagents, the cells were lysed with an ice-cold lysis buffer consisting of 20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol (vol./vol.), 100 mM NaF, 10 mM sodium pyrophosphate, 1% TritonX-100, 1 mM Na 3 VO 4 , 1 mM PMSF, 10 mg/mL antipain, 10 mg/mL leupeptin and 10 mg/mL aprotinin, before being centrifuged at 14,000 rpm and 4 C for 15 min. The resulting supernatant was collected and used for subsequent analyses. The protein concentration of each cell lysate was determined by using BCA reagents (Pierce, Rockford, IL, USA). The proteins were transferred to polyvinylidene difluoride membranes after SDS-PAGE, and after blocking, the membranes were incubated with the specific primary antibody and then with the peroxidase-conjugated secondary antibody. Blots were developed with a chemiluminescence kit according to the manufacturer's instructions (Nacalai Tesque, Kyoto, Japan). The band intensity was quantified by using an LAS-4000 mini imaging analyzer (Fujifilm, Tokyo, Japan). The stimulators resveratrol and "-viniferin, and the inhibitor ZnPP IX were each dissolved in DMSO and then added to the medium at a final DMSO concentration of 0.1%. The same final concentration of DMSO was used in place of these reagents for control treatments. Western blotting was not affected by DMSO under these experimental conditions. Statistical analysis. All values in the figures are presented as the mean AE SE. A one-way analysis of variance (ANOVA) was used to assess significant differences between treatment groups. Duncan's multiple-range test was used to compare multiple group means when the treatment was found to have a significant effect, and Student's t test was applied when two groups were compared. A value of p < 0:05 was considered statistically significant.
Results
"-Viniferin was more effective than resveratrol in inhibiting PDGF-induced proliferation and migration in VSMCs
We examined the anti-proliferative effects of resveratrol and "-viniferin on VSMCs at concentrations of 10, 20, and 30 mM. Both compounds suppressed PDGFinduced cell proliferation in a concentration-dependent manner and reduced the cell number in the absence of PDGF (Fig. 1B) . The anti-proliferative rate of "-viniferin at 20 mM was significantly higher than that of resveratrol at both 20 mM and 30 mM. The two compounds also suppressed PDGF-dependent cell migration (Fig. 1C) . "-Viniferin at 10 mM more efficiently inhibited migration than resveratrol did at 30 mM. These data suggest that "-viniferin was more effective than resveratrol in inhibiting PDGF-induced proliferation and migration in VSMCs.
Nitric oxide was more effectively produced by "-viniferin than by resveratrol, and involved in inhibiting the cell proliferation induced by these compounds
We investigated whether "-viniferin and resveratrol would produce NO, because NO can suppress the proliferation of VSMCs. 12, 13, 31, 32) Both compounds dose-dependently and significantly increased NO production ( Fig. 2A) . The NO production rate by "-viniferin at 20 mM and 30 mM was significantly higher than that by resveratrol at 30 mM. It should be noted that A, Chemical structure of resveratrol and "-viniferin. B, Serum-starved VSMCs (3 Â 10 3 cells/well) plated on to 96-well plate were treated for 48 h with 10, 20, or 30 mM of resveratrol or "-viniferin in the presence or absence of 20 ng/mL of PDGF, and the proliferation was assessed by an MTS assay according to the manufacturer's instructions. C, Serum-starved VSMCs were treated with 30 mM resveratrol or 10 mM "-viniferin with or without PDGF to assess the cell migration by using a modified Boyden chamber method as described in the Materials and Methods section. Data are the mean AE SE of three separate experiments, each performed in triplicate for B and in duplicate for C. Ã p < 0:05 vs. untreated cells, # p < 0:05 vs. PDGF alone, x p < 0:05.
we used 10 mM "-viniferin and 30 mM resveratrol in all of the subsequent experiments, because 10 mM "-viniferin and 30 mM resveratrol exhibited an equivalent level of effect on cell proliferation and NO production. The antiproliferative effect of "-viniferin and resveratrol was inhibited by adding L-NAME, a general inhibitor of NO synthase (NOS) (Fig. 2B) . Both compounds increased the protein level of iNOS, although the time dependency was different between the two (Fig. 2C and D) ; the increase in iNOS proteins peaked 3-6 h and 12 h after respectively stimulating by 30 mM resveratrol and 10 mM "-viniferin. These data demonstrate that both "-viniferin and resveratrol inhibited PDGF-induced cell proliferation through the induction of iNOS expression and that "-viniferin was more effective than resveratrol in producing NO.
"-Viniferin and resveratrol prevented intracellular ROS production
We examined the effects of "-viniferin and resveratrol on ROS generation in VSMCs, because ROS contributes to the VSMC proliferation and migration induced by various stimuli including PDGF and is closely associated with the pathogenesis of atherosclerosis. 33) Exposure of the cells to PDGF caused a marked increase in intracellular ROS (Fig. 3) . This increase was completely suppressed by the 24-h pretreatment of the cells with the two compounds. The basal level of intracellular ROS was also decreased by pretreating with these reagents. It is therefore considered that "-viniferin and resveratrol were effective in suppressing ROS generated in VSMCs, regardless of the presence or absence of a stimulator such as PDGF. A, "-Viniferin induced NO production in VSMCs more effectively than resveratrol. Nitric oxide production was determined by using DAF-2DA as described in the Materials and Methods section. B, NOS inhibitor L-NAME suppressed the inhibitory effect of resveratrol and "-viniferin on PDGF-induced VSMC proliferation. Serum-starved VSMCs were treated with 30 mM resveratrol or 10 mM "-viniferin in the presence or absence of 1 mM L-NAME with or without PDGF (20 ng/mL), and the proliferation was assessed by an MTS assay as described in the Materials and Methods section. Data are the mean AE SE of three separate experiments, each performed in triplicate for A and B.
Ã p < 0:05 vs. untreated cells, # p < 0:05 vs. PDGF alone, x p < 0:05. C and D, Serum-starved VSMCs were treated with 30 mM resveratrol (C) or 10 mM "-viniferin (D) for the indicated periods of time, and the protein levels of iNOS were determined by western blotting. Representative data are shown (upper panels). The band intensity of iNOS was normalized to the amount of -tubulin and is expressed as the ratio (%) to the strongest band as the control value (lower panels). Data are the mean AE SE of three separate experiments.
Ã p < 0:05 vs. the strongest band.
Hemeoxygenase-1 protein expression was induced by "-viniferin and resveratrol via Nrf2 activation, and was involved in inhibiting cell proliferation by these compounds
We investigated the effect of "-viniferin and resveratrol on the expression of antioxidant enzyme HO-1 that is implicated in the proliferation and migration of VSMCs. 14, 34) Both compounds induced HO-1 protein expression, although the effect of "-viniferin was more sustained than that of resveratrol ( Fig. 4A and B) . We detected the nuclear protein level of Nrf2, since Nrf2 is a transcription factor to up-regulate HO-1 expression. Both "-viniferin and resveratrol induced Nrf2 accumulation in the nuclear fraction, although the effect of "-viniferin was more sustained than that of resveratrol, like the HO-1 expression (Fig. 4C and D) . The induction of HO-1 expression by both compounds was suppressed by Nrf2 siRNA (Fig. 4E and F) , suggesting that Nrf2 was critically involved in the "-viniferin-and resveratrol-dependent HO-1 expression. We further investigated whether the HO-1 expression would contribute to the "-viniferin-and resveratrol-dependent inhibition of VSMC proliferation by PDGF. HO-1 inhibitor ZnPP IX significantly, but not completely, suppressed the anti-proliferative effect of both compounds (Fig. 4G) , revealing that the induced HO-1 expression was implicated, at least in part, in this antiproliferative effect.
"-Viniferin and resveratrol accumulated Nrf2 in the nucleus by different mechanisms
Mitogen-activated protein kinases (MAPKs) or the phosphatidylinositol 3-kinase (PI3K)-Akt pathway contribute to the accumulation of Nrf2 in the nucleus with subsequent expression of HO-1 which is involved in cytoprotective and anti-inflammatory responses. 14, 34, 35) We therefore examined the involvement of these kinases in the pathways elicited by "-viniferin and resveratrol. Whereas "-viniferin obviously induced the phosphorylation of Akt, p38, and ERK1/2, resveratrol phosphorylated only Akt and p38 ( Fig. 5A and B) . The resveratroldependent Nrf2 increase was inhibited by PI3-kinase inhibitor LY294002, but not by ERK pathway inhibitor U0126 or by p38 inhibitor SB203580 (Fig. 5C ). In contrast, the "-viniferin-induced increase was suppressed by U0126 and SB203580, but not by LY294002 (Fig. 5D ). These data suggest that resveratrol accumulated Nrf2 in the nucleus via the PI3K/Akt pathway, but not the p38 and ERK pathways, whereas the p38 and ERK pathways mediated the "-viniferindependent Nrf2 accumulation.
Discussion
The present paper is the first report indicating the direct effect of "-viniferin on cultured VSMCs. We found several things concerning the functions of resveratrol and "-viniferin in these cells. First, both "-viniferin and resveratrol inhibited PDGF-induced proliferation and migration of VSMCs. Both compounds exhibited the anti-proliferative effect by inducing NO generation and Nrf2-mediated HO-1 expression. Second, "-viniferin was more effective than resveratrol in these effects. Third, the underlying molecular mechanism for these effects differed between the two compounds, at least in Nrf2 activation; the PI3K-Akt pathway, but not ERK and p38, mediated resveratrolinduced Nrf2 activation, whereas ERK and p38, but not the PI3K-Akt pathway, were involved in "-viniferindependent Nrf2 activation. Together with the fact that the "-viniferin content was comparable with or higher than the resveratrol content, depending on the type of , and then subjected to western blotting for phosphorylated Akt, p38 and ERK, and -tubulin. Representative data are shown (left panels). The bands of ERK1/2 were overexposed to emphasize that there was no increase in the band intensity. The band intensity of each kinase was quantified with an LAS-4000 imaging analyzer, and the results normalized to the amount of -tubulin are expressed as the ratio (%) to the strongest band as the control value for each kinase (right panels).
Ã p < 0:05 vs. the value of the strongest band. C and D, Serum-starved VSMCs were cultured for 12 h with 30 mM resveratrol (C) or 10 mM "-viniferin (D) in the presence or absence of 30 mM LY294002 (LY), 10 mM SB203580 (SB), or 30 mM U0126 (U0). Representative data are shown (upper panels). The band intensity was quantified with an LAS-4000 imaging analyzer. The values for the Nrf2 band were normalized to the amount of lamin B and expressed as a percentage of the value for the resveratrol or "-viniferin treatment alone (lower panels). Data are the mean AE SE of three separate experiments.
Ã p < 0:05 vs. the value for the resveratrol or "-viniferin treatment alone. , and HO-1 protein expression was analyzed by western blotting. Representative data are shown (upper panels). The band intensity of HO-1 (A and B) and Nrf2 (C and D) was respectively normalized to the amount of -tubulin and lamin B, and is expressed as the ratio (%) to the strongest band as the control value (lower panels). Data are the mean AE SE of three separate experiments.
Ã p < 0:05 vs. the strongest band. E and F, Serum-starved VSMCs were transfected with control siRNA or Nrf2 siRNA by using lipofectamineÔ RNAiMAX, left for 48 h, and then incubated for another 24 h with 30 mM resveratrol (E) or 10 mM "-viniferin (F). The cells were then subjected to western blotting for Nrf2, HO-1, and -tubulin. Representative data are shown (upper panels). The band intensity of HO-1 (A and B) and Nrf2 (C and D) was respectively normalized to the amount of -tubulin and lamin B, and is expressed as a percentage of the value for resveratrol or "-viniferin alone in the presence of scr (lower panels). Data are the mean AE SE of three separate experiments.
Ã p < 0:05 vs. the value for resveratrol or "-viniferin alone with scr. G, HO-1 inhibitor ZnPP IX abolished the resveratrol-and "-viniferin-dependent inhibition of VSMC proliferation elicited by PDGF. Serum-starved VSMCs were incubated with 20 ng/mL of PDGF in the presence or absence of 1 mM ZnPP IX with or without 30 mM resveratrol or 10 mM "-viniferin. The proliferation after 48 h was assessed by an MTS assay as described in the Materials and Methods section. Data are the mean AE SE of four separate experiments, each performed in triplicate.
Ã p < 0:05 vs. untreated cells, # p < 0:05 vs. PDGF alone, x p < 0:05.
red wine and the stage of noble rot development of the grapes, 15, 16) these data suggest that both "-viniferin and resveratrol were key compounds preventing the pathogenesis of atherosclerosis and that "-viniferin may also be a strong candidate to explain the ''French paradox.'' Our data suggest that resveratrol activated Akt with subsequent accumulation of Nrf2 in the nucleus followed by HO-1 expression, thereby inhibiting the proliferation of VSMCs. These data are in good agreement with a very recent report indicating that HO-1 inhibitor ZnPP IX suppressed the inhibitory effect of resveratrol on VSMC proliferation.
14) It is considered that similar signaling pathways were also activated by "-viniferin, except for the involvement of ERK and p38 instead of Akt, because ZnPP IX partially but significantly reversed the "-viniferin-dependent inhibition of VSMC proliferation. Our data also show that NO was critically implicated in this inhibitory effect of the two compounds, because general NO synthase inhibitor L-NAME suppressed their effect. Moreover, Wegiel et al. 36) have very recently demonstrated that carbon monoxide produced by HO-1 led to NO generation via endothelial NOS activation in vascular endothelial cells. Although further experiments are necessary, such a relationship of HO-1 with NO production may exist on the resveratrol and "-viniferin signaling pathways in VSMCs.
We found that the inhibition of PDGF-induced ROS generation by pretreating the cells with resveratrol and "-viniferin was also critically associated with their inhibitory effect on VSMC proliferation (Fig. 3) . It is known that HO-1 generates biliverdin, which is subsequently converted to bilirubin by biliverdin reductase, and that these two heme metabolites are efficient scavengers of ROS and inhibit VSMC proliferation. 37, 38) An elevation in serum bilirubin concentration markedly reduces the risk of coronary artery disease and atherosclerosis.
37) The induction of HO-1 expression by resveratrol and "-viniferin leading to biliverdin and bilirubin production may therefore play an important role in reducing increased ROS and the risk of these diseases. In addition to HO-1 expression, there are several possibilities concerning the mechanism by which ROS is decreased by these compounds, because the inhibitory effect of ZnPP IX, an inhibitor of HO-1, was partial, but not complete (Fig. 4G) . These possibilities are i) direct scavenging of ROS, ii) inhibition of NADPH oxidase, a main generator of ROS in VSMCs, and iii) other antioxidant enzymes such as catalase, glutathione peroxidase, and superoxide dismutase. The expression of glutathione peroxidase and superoxide dismutase is particularly up-regulated by Nrf2.
Our data indicate that resveratrol and "-viniferin had the same effects on VSMCs, although "-viniferin was more effective than resveratrol. Interestingly, "-viniferin also exhibited more sustained effects than resveratrol on iNOS induction and Nrf2 accumulation in the nucleus with subsequent HO-1 expression. It is not clear why such a difference in time dependency occurred between the two compounds. The different activating pathway(s) for Nrf2 expression by these compounds (Fig. 5C and D) may have induced this difference, while another possibility is the stability of the compounds in the cell. Resveratrol may therefore be more rapidly degraded than "-viniferin which would lead to a more transient effect of resveratrol than that of "-viniferin, including iNOS induction.
It is not clear why "-viniferin was more effective than resveratrol in inhibiting PDGF-induced VSMC proliferation and migration. Both compounds have different target molecules from each other, because the Nrf2 activating pathways differ. We need to identify their direct target molecules and understand the pathways leading to HO-1 expression, NO production, and reducing intracellular ROS to elucidate the molecular mechanisms for their differing potency.
